Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients

Aprea Therapeutics, Inc.

2025-Q1 EPS reported -$0.66

Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.
Operating loss $4.1M (Q1 2025) vs $3.1M (Q1 2024); R&D spending up $0.9M on APR-1051 and ATRN-119 trials.
ATRN-119 ABOYA-119 trial: 3 patients at 550mg BID had tumor shrinkage of 7%, 14%, and 21% below RP2D.
APR-1051 ACESOT-1051 trial enrolling at 100mg QD; next cohort 150mg; preliminary efficacy data expected H2 2025.
Entered Material Transfer Agreement with MD Anderson to study APR-1051 in head and neck cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.